Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children ≥6 and ≤14 years of age~2. Enrolled in one of the selected primary schools in the region~3. Infected with schistosomiasis (i.e. Schistosoma spp. eggs in urine and/or stool)~4. Informed consent from parents/guardians signed~Exclusion Criteria:~1. History of, or ongoing, epilepsy or psychiatric illness (I.e. recent history of depression, generalized anxiety disorder; history of psychosis, schizophrenia or other major psychiatric disorders) or known hypersensitivity to one of the three study drugs~2. Chronic medication for any reason~3. Any severe underlying illness, including severe malnutrition or severe chronic schistosomiasis, based on clinical judgement~4. Any febrile illness~5. Exposure to PZQ or ACT within the three previous months.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Praziquantel (Type: ACTIVE_COMPARATOR): Participants in this arm will receive one dose of PZQ at baseline at 40 mg/kg.
- Artesunate-Mefloquine (Type: EXPERIMENTAL): Participants in this arm will receive the Artesunate-Mefloquine (fixed-drug)combination at 4 mg/kg artesunate and 8 mg/kg mefloquine at 3 consecutive days. This will be repeated twice; at week 6 and week 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).